Stem Cell Transplant to Treat Patients With Systemic Sclerosis
NCT00058578 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2020-01-18
Summary
Systemic Sclerosis is a disease that may be caused by the immune system reacting against skin and certain organs. It is possible, that by changing the immune system we can modify the progression of this disease.
Stem cells are created in the bone marrow. They mature into different types of blood cells that are needed including red blood cells, white blood cells, and platelets. In this study, we will stimulate the bone marrow to make extra stem cells. Next we will collect the stem cells, select specific cells, and store them. We will then give high dose chemotherapy that will destroy the patients immune system. We will then give back the selected stem cells we collected. We believe that these selected stem cells may be able to "re-create" the immune system without the portion that causes Systemic Sclerosis.
The purpose of this study is to try to discover if stem cell transplantation can help patients with Systemic Sclerosis. We will also try to learn what the side effects are of this treatment in patients with Systemic Sclerosis. We hope that this treatment will help to relieve the symptoms patients are experiencing, although we do not know if it will.
Conditions
Interventions
- DRUG
- DRUG
-
Mesna
- DRUG
-
G-CSF
- PROCEDURE
-
Leukopheresis
- PROCEDURE
-
Total Body Irradiation
Sponsors & Collaborators
-
The Methodist Hospital Research Institute
collaborator OTHER -
Center for Cell and Gene Therapy, Baylor College of Medicine
collaborator OTHER -
Baylor College of Medicine
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-06-30
- Completion
- 2004-06-30
Countries
- United States
Study Locations
More Related Trials
-
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
NCT01189786 ·Status: RECRUITING ·Phase: NA
-
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00005854 ·Status: COMPLETED ·Phase: PHASE2
-
HD Melphalan and SCT in Patients With IGDD or LCDD
NCT00681044 ·Status: TERMINATED ·Phase: PHASE2
-
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
NCT02258490 ·Status: NO_LONGER_AVAILABLE
-
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00005092 ·Status: COMPLETED ·Phase: PHASE1
-
Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA
NCT00455312 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia
NCT00002718 ·Status: COMPLETED ·Phase: PHASE2
-
Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
NCT00578266 ·Status: COMPLETED ·Phase: PHASE1
-
Stem Cell Transplant for Hematologic Diseases
NCT00058825 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
NCT00005988 ·Status: COMPLETED ·Phase: PHASE1
-
Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment
NCT00749164 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
NCT00006379 ·Status: COMPLETED ·Phase: PHASE2
-
Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis
NCT00578435 ·Status: COMPLETED ·Phase: PHASE2
-
Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia
NCT00002789 ·Status: COMPLETED ·Phase: PHASE3
-
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00004232 ·Status: COMPLETED ·Phase: PHASE1
-
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
NCT00005852 ·Status: TERMINATED ·Phase: PHASE2
-
Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation
NCT00809250 ·Status: COMPLETED ·Phase: PHASE1
-
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
NCT01174108 ·Status: RECRUITING ·Phase: PHASE2
-
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
NCT01067287 ·Status: COMPLETED ·Phase: PHASE2
-
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
NCT00053989 ·Status: COMPLETED ·Phase: PHASE2
-
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
NCT03622788 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
NCT00684255 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease
NCT00972660 ·Status: UNKNOWN ·Phase: PHASE2
-
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
NCT00385788 ·Status: COMPLETED ·Phase: PHASE2
-
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
NCT00005797 ·Status: COMPLETED ·Phase: PHASE2